Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898515 | 0.71 | NR3C2 (0.32) | CYP3A4P2RX7 | |
| SCHEMBL899066 | 0.71 | MAPK14 (0.37) | CYP3A4LMNAP2RX7 | |
| SCHEMBL899021 | 0.71 | NR3C2 (0.34) | CYP3A4P2RX7 | |
| SCHEMBL899181 | 0.70 | NR3C2 (0.31) | CYP3A4P2RX7 | |
| SCHEMBL898961 | 0.69 | KEAP1 (0.36) | CYP3A4P2RX7 | |
| SCHEMBL898051 | 0.65 | KMT2A (0.41) | — | |
| SCHEMBL28135167 | 0.64 | HSD11B1 (0.35) | CYP3A4P2RX7HSD11B1 | |
| SCHEMBL1507033 | 0.64 | KCNN4 (0.43) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL29727285 | 0.64 | KCNN4 (0.43) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL899144 | 0.64 | NR3C2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | CYP1A1, CYP1B1, CYP2E1 | CYP3A4 27/4885CYP2C9 33/4885CYP2C19 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.